Peripheral neuropathies: Subcutaneous immunoglobulin — the future of CIDP treatment?

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This finding represents an important step in the management of patients with immunoglobulin-responsive CIDP, with considerable implications for the cost of treatment and, most importantly, for these patients' quality of life.